商务合作
动脉网APP
可切换为仅中文
AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of
德克萨斯州奥斯汀,2026年11月11日(环球电讯社)——专注于开发结节性硬化症(TSC)相关癫痫疗法的生物技术公司Filana Therapeutics, Inc.(纳斯达克股票代码:FLNA)今日宣布任命
Jill M. Quigley
吉尔·M·奎格利
to its Board of Directors (the “Board”). Ms. Quigley brings additional executive leadership experience to Filana, having previously scaled biopharma companies through pivotal stages of drug development, financing, and value creation.
致其董事会(“董事会”)。奎格利女士为 Filana 带来了额外的高管领导经验,她此前曾带领生物制药公司度过药物开发、融资和价值创造的关键阶段,并实现规模化发展。
“On behalf of the Board, I welcome Jill to Filana. Her record of guiding companies through financings and strategic growth will broaden the expertise around our Board table,” commented
“我代表董事会欢迎吉尔加入菲拉纳。她在引导公司完成融资和实现战略增长方面的卓越记录,将丰富我们董事会的专业能力。”评论道
Claude Nicaise, MD, Chairman of the Board
克劳德·尼凯斯医学博士,董事会主席
of Filana Therapeutics. “This appointment reflects our continued focus on aligning the Board with Filana Therapeutics’ evolving needs as the Company moves simufilam through clinical development.”
Filana Therapeutics 表示:“此次任命反映了我们在公司推进 simufilam 的临床开发过程中,持续致力于使董事会与 Filana Therapeutics 不断发展的需求保持一致。”
“Jill joins Filana at an exciting time, as we prepare for our planned Phase 2a clinical study of simufilam in TSC-related epilepsy, with patient screening expected to begin by the first quarter of 2027,” said
“吉尔加入Filana正值激动人心的时刻,因为我们正为计划中的simufilam治疗TSC相关癫痫的2a期临床研究做准备,预计患者筛查将于2027年第一季度开始,”
Rick Barry, President and Chief Executive Officer
里克·巴里,总裁兼首席执行官
of Filana Therapeutics, Inc. “We believe in the scientific rationale supporting our program in TSC, and I look forward to collaborating closely with Jill as we work to create value for patients, their families, and shareholders.”
Filana Therapeutics, Inc. 的表示:“我们坚信支持我们在结节性硬化症(TSC)项目中的科学依据,并期待与 Jill 密切合作,共同为患者、其家属及股东创造价值。”
Jill M. Quigley, Independent Director
吉尔·M·奎格利,独立董事
of Filana Therapeutics, added, “I am pleased to join the Filana Therapeutics Board and eager to contribute my experience as the Company advances simufilam through clinical development. I have been particularly impressed by Filana’s commitment to patients and its science-driven approach to developing a potential new treatment for TSC-related epilepsy.”.
Filana Therapeutics 的表示:“我很高兴加入 Filana Therapeutics 董事会,并渴望在公司推进 simufilam 的临床开发过程中贡献我的经验。Filana 对患者的承诺及其以科学为驱动的开发结节性硬化症(TSC)相关癫痫潜在新疗法的方法,令我印象深刻。”
About Jill M. Quigley
关于吉尔·M·奎格利
Jill Quigley brings more than 20 years of biotechnology industry leadership experience to Filana. Her prior work encompasses executive management, corporate operations, legal affairs, financing, and board membership. Building on her initial expertise in legal affairs, she has broadened her capabilities and experience, ultimately serving as head of operations and chief executive of biotechnology firms developing innovative products for rare diseases..
吉尔·奎格利为菲拉纳带来了超过20年的生物技术行业领导经验。她此前的工作涵盖高层管理、企业运营、法律事务、融资以及董事会成员职务。在法律事务的初始专业基础上,她不断拓展自身能力与经验,最终担任多家致力于开发罕见病创新产品的生物技术公司的运营负责人及首席执行官。
Ms. Quigley has worked extensively with public and private biotechnology companies, established domestic and international operations, and helped lead major financing rounds. She is currently the CEO of a preclinical biotechnology company since November 2026 and recently served as Entrepreneur in Residence at J.P.
奎格利女士曾与众多公立和私立生物技术公司开展广泛合作,建立国内及国际业务运营,并协助主导多轮重大融资。自2026年11月起,她担任一家临床前生物技术公司的首席执行官,并最近曾在摩根大通担任驻企企业家。
Morgan Life Sciences Private Capital from November 2025 to November 2026. She served on the board of directors of Terns Pharmaceuticals, Inc. (formerly NASDAQ: TERN) from December 2020 until its acquisition by Merck in May 2026, where she also served as a senior advisor and strategy officer on an interim basis from October 2023 through February 2024.
2025年11月至2026年11月,任职于摩根生命科学私募资本部门。她自2020年12月起担任Terns Pharmaceuticals, Inc.(前纳斯达克股票代码:TERN)董事会董事,直至该公司于2026年5月被默克公司收购;在此期间,她还于2023年10月至2024年2月临时担任高级顾问兼战略官。
Ms. Quigley served on the board of Chemomab Therapeutics Ltd. (NASDAQ: CMMB) from 2022 to 2026..
奎格利女士于2022年至2026年期间担任Chemomab Therapeutics Ltd.(纳斯达克股票代码:CMMB)的董事会成员。
Previously, Ms. Quigley was the Chief Executive Officer of Genuiti Therapeutics, Inc. from September 2023 through June 2025. Prior to that, Ms. Quigley was Chief Operating Officer at Passage Bio, Inc., a publicly traded gene therapy company, from November 2018 to December 2021, and before that she served as Chief Executive Officer and General Counsel of Nutrinia, Ltd., a developer of treatments for rare gastrointestinal diseases..
此前,奎格利女士于2023年9月至2025年6月担任Genuiti Therapeutics, Inc.的首席执行官。在此之前,她于2018年11月至2021年12月担任公开上市的基因治疗公司Passage Bio, Inc.的首席运营官。更早之前,她曾担任罕见胃肠道疾病治疗开发商Nutrinia, Ltd.的首席执行官兼总法律顾问。
Earlier in her career, Ms. Quigley was Senior Counsel at NPS Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Shire plc; served as Corporate Counsel for Pharmasset, Inc., a publicly traded biotechnology firm acquired by Gilead Sciences, Inc.; and served as Assistant Corporate Counsel for publicly traded Integra LifeSciences Holdings Corporation..
奎格利女士在职业生涯早期曾担任NPS Pharmaceuticals, Inc.的高级法律顾问,该公司是一家被夏尔制药(Shire plc)收购的上市生物技术公司;她还曾担任Pharmasset, Inc.的公司法律顾问,该公司是一家被吉利德科学公司(Gilead Sciences, Inc.)收购的上市生物技术企业;此外,她还曾担任上市公司Integra LifeSciences Holdings Corporation的助理公司法律顾问。
Ms. Quigley practiced as an Associate with the law firm Dechert LLP. She holds a BA degree from American University and a JD from Rutgers School of Law.
奎格利女士曾在德杰律师事务所(Dechert LLP)担任执业律师。她拥有美国大学的文学学士学位和罗格斯大学法学院的法学博士学位。
About Filana Therapeutics, Inc.
关于Filana Therapeutics, Inc.
Filana Therapeutics, Inc. (NASDAQ: FLNA) is a biotechnology company focused on developing novel therapies to modulate filamin A for the treatment of central nervous system (CNS) disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A..
Filana Therapeutics, Inc.(纳斯达克股票代码:FLNA)是一家生物技术公司,专注于开发调节丝状蛋白A的新型疗法,用于治疗中枢神经系统(CNS)疾病,如结节性硬化症(TSC)相关癫痫,以及其他与丝状蛋白A失调或过表达相关的疾病。
For more information, please visit:
更多信息,请访问:
https://www.FilanaTx.com
https://www.FilanaTx.com
For More Information Contact:
如需更多信息,请联系:
Investors
投资者
Mike Moyer
迈克·莫耶
mmoyer@lifesciadvisors.com
mmoyer@lifesciadvisors.com
Company
公司
Eric Schoen, Chief Financial Officer
埃里克·肖恩,首席财务官
(512) 501-2450
(512) 501-2450
ESchoen@FilanaTx.com
ESchoen@FilanaTx.com
IR@FilanaTx.com
IR@FilanaTx.com
Cautionary Note Regarding Forward-Looking Statements:
关于前瞻性陈述的警示说明:
This news release contains forward-looking statements that may include but are not limited to statements regarding: the anticipated contributions of Ms. Quigley to the Board and the Company; the timing and plans to initiate and conduct clinical studies with simufilam in TSC-related epilepsy; the design, structure, duration, objectives, endpoints, patient population, conduct, enrollment, completion, and potential results of our planned Phase 2a clinical trial; our ability to work with clinical investigators and the TSC community to advance the trial efficiently; the potential for simufilam as a treatment for TSC-related epilepsy and other potential indications; our ability to create value for patients, their families and stockholders; and the timing of anticipated milestones.
本新闻稿包含前瞻性陈述,包括但不限于以下方面的陈述:奎格利女士对董事会及公司的预期贡献;启动和开展西米夫兰(simufilam)治疗结节性硬化症(TSC)相关癫痫临床研究的时间安排与计划;我们计划的2a期临床试验的设计、结构、持续时间、目标、终点指标、患者人群、实施、入组、完成情况及潜在结果;我们与临床研究者及结节性硬化症社群合作以高效推进试验的能力;西米夫兰作为结节性硬化症相关癫痫及其他潜在适应症治疗药物的潜力;我们为患者、其家属及股东创造价值的能力;以及预期里程碑事件的时间安排。
These statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “look forward”, “may”, “pending”, “plan”, “possible”, “potential”, “prepare”, “will”, and other words and terms of similar meaning. .
这些陈述可以通过诸如“预期”、“之前”、“相信”、“可能”、“预计”、“预测”、“打算”、“期待”、“也许”、“待定”、“计划”、“有可能”、“潜在”、“准备”、“将”等词语以及其他具有类似含义的词语和术语来识别。
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to our ability to initiate, enroll, conduct, and complete the planned Phase 2a study of simufilam in TSC-related epilepsy; our ability to engage clinical trial sites and participants; our ability to work effectively with clinical research organizations, vendors, investigators, patient advocacy organizations, and the TSC community; the expected impact of new members of the Board of Directors, and other risks inherent in drug discovery and development or specific to Filana Therapeutics, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, Form 10-Q for the quarter ended September 30, 2026 and subsequent reports filed or to be filed with the U.S.
此类陈述基于我们对未来事件的当前预期和预测。此类陈述仅截至本新闻稿发布之日有效,并受多种风险、不确定性和假设的影响,包括但不限于与以下方面相关的风险:我们启动、招募、开展并完成计划中的simufilam治疗TSC相关癫痫的2a期临床研究的能力;我们招募临床试验机构和参与者的能力;我们与临床研究组织、供应商、研究者、患者倡导组织以及TSC社区有效合作的能力;新任董事会成员带来的预期影响;以及药物发现和开发中固有的其他风险,或Filana Therapeutics, Inc.特有的风险,正如我们在截至2025年12月31日的年度10-K表报告、截至2026年9月30日的季度10-Q表报告以及随后向美国证券交易委员会提交或将要提交的报告中“风险因素”一节所述。
Securities and Exchange Commission (SEC). The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
美国证券交易委员会(SEC)。前述内容列出了可能导致实际结果与任何前瞻性陈述中的预期存在差异的诸多因素,但并非全部。鉴于这些风险、不确定性和假设,本新闻稿中讨论的前瞻性陈述及事件具有固有的不确定性,可能不会发生,且实际结果可能与前瞻性陈述中预期或暗示的结果存在重大不利差异。
Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our busin.
因此,您不应将前瞻性陈述视为对未来事件的预测。除非法律另有要求,我们不承担任何更新或修订任何前瞻性陈述的意图或责任。有关这些风险以及与我们业务相关的其他风险的更多信息,
www.sec.gov
www.sec.gov
.
。
All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population.
我们所有在研的医药资产均为研究性候选产品。这些产品尚未获得任何司法管辖区的任何监管机构批准用于任何医疗适应症,且其在任何患者群体中的安全性、有效性或其他理想属性(如有)尚未得到确立。
Consequently, none of our product candidates is approved or available for sale anywhere in the world..
因此,我们的任何候选产品均未在全球任何地方获得批准或上市销售。
Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish..
我们来自早期临床试验或临床前研究的临床结果可能无法预示后期或更大规模临床试验的未来结果,也不能确保获得监管批准。您不应过度依赖这些陈述或我们呈现或发布的任何科学数据。
We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein.
我们从事新药发现与开发业务。我们的研发活动周期长、复杂、成本高昂,且涉及高度风险。我们的普通股持有人应仔细阅读我们完整的10-K表格年度报告及后续的10-Q表格季度报告,包括其中所载的风险因素。
Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested..
由于风险是药物发现和开发过程中的基本要素,提醒您除非您已准备好承受所投资资金的全部损失,否则不要投资于我们公开交易的证券。